Recognizing and treating urogenital atrophy in postmenopausal women.
Urogenital atrophy resulting from postmenopausal estrogen deficiency has numerous clinical effects, including vaginal dryness, sexual dysfunction, urinary incontinence, and recurrent urinary tract infections (UTIs), all of which can cause significant distress and reduction in quality of life. Although nearly one third to one half of postmenopausal women experience these symptoms, they are often overlooked because patients may be reluctant to discuss them and clinicians fail to screen for them. As these symptoms are unlikely to resolve without treatment, the prompt diagnosis and treatment of urogenital atrophy is essential. Estrogen therapy, administered either locally or systemically, provides significant relief from symptoms related to urogenital atrophy. However, systemic estrogen therapy is contraindicated in some women and may not be accepted in women without other menopausal symptoms. Local low-dose vaginal estrogen therapy, in the form of vaginal estrogen tablets, creams, or rings, has been shown to reduce dyspareunia and vaginal dryness, restore vaginal pH, and restore normal vaginal cytology. All forms of vaginal estrogen therapy are effective and well tolerated, although vaginal tablets and rings may have fewer adverse effects and have higher rates of adherence than creams.
Goldstein
Irwin
I
San Diego Sexual Medicine Alvarado Hospital and Department of Surgery, University of California at San Diego, California, USA. dr.irwingoldstein@gmail.com
D001284:Atrophy / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D003681:Dehydration / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D015914:Estrogen Replacement Therapy / Q000379:methods; D005260:Female; D006801:Humans; D008875:Middle Aged; D010808:Physical Examination; D017698:Postmenopause; D014621:Vagina / Q000473:pathology*; D014623:Vaginal Diseases / Q000188:drug therapy / Q000209:etiology / Q000473:pathology; D014844:Vulva / Q000473:pathology*